Your use of this site constitutes acceptance of these Terms and Conditions as at the date of your first use of the site. The Urological Cancer Trust Fund reserves the right to change these Terms and Conditions at any time by posting changes online. Your continued use of this site after changes are posted constitutes your acceptance of this agreement as modified.
We make every effort to ensure that this website reflects up-to-date, objective and accurate facts about prostate cancer in Malaysia. It is our hope that these will complement your medical advice and help you to make any decisions that you may face. The information provided on this website is designed to support, not replace, the relationship that may exist between you and your doctor.
To avoid any ambiguity, our website is meant to provide general education and information about prostate cancer. The Fund shall not be responsible for any damages or liabilities arising from your dependence on the website’s content. We always take the position that our website does not substitute professional medical advice, diagnosis or treatment.
We are agreeable for other organisations who share our mission and values to link to our website. However, we do not grant blanket permission for our information and content to be used elsewhere. We strive to keep our material up to date with the latest medical research and data. Unregulated, unacknowledged reproduction of our information may lead to out of date versions being in use, which is out of our control.
If you find our material is helpful, please link to it directly. This ensures that it remains relevant and up-to-date. Please contact the Urological Cancer Trust Fund via the Contact Us page if you have a specific query about information material.
We are a Malaysia-based entity and our materials are relevant only to Malaysia. We do not produce information about the situation in other countries. If you are not seeking treatment in Malaysia, and choose to download our information, we are not responsible for any differences of emphasis you discover between the Malaysian situation and that in your country of treatment.
We strive to provide evidence-based medical information. This means that we adhere to broadly scientific principles of appraisal. We make no recommendations about any particular course of action involving medical consultation, screening, diagnosis and treatment, as no publicly available data exists to generate the evidence for such recommendations.
All content, information, blue moustache logo and visuals on the website remain the properties of the Urological Cancer Trust Fund.
This website links to other websites. Users expect this, and by convention this is regarded as a useful and essential feature of any information website. It does not, however, represent any kind of recommendation or endorsement by us of the accuracy of the content of external websites. We provide links that we hope are of interest and use. It is up to you to decide which links to follow. We are not responsible for the details of what you find there.
We do not actively seek advertising for the website. Any requests made will be assessed on a case to case basis. Advertising and other promotional material that may appear will be presented so that it is quite clearly an advertisement.
We will not give a favourable response to any company or organisation seeking to sell treatments or services directly to men with prostate cancer which imply, suggest or claim that they can cure it.
Should you have further queries about this policy, please contact us.
We are committed to protecting your personal information and being transparent about what information we hold, whether you are a service user, potential donor, volunteer, campaigner or employee. We promise to respect any personal data you share with us, or that we get from other organisations and keep it safe.
We are committed to adhering to Malaysia’s Personal Data Protection Act 2010. We will mainly use your data to:
We will sometimes use profiling and screening techniques to analyse geographic, demographic and other information relating to you to better understand your interests and preferences in order to contact you with the most relevant communications. Personal details collected this way will only be used to provide you with information you would reasonably expect or have agreed to. We do this because it allows us to understand more about the background and interests of the people who support us, allowing us to target our resources effectively; a key priority for our supporters. In doing this, we may use additional information from publicly available sources where it is appropriate and this specific activity allows us to make suitable requests to individuals who may have the means and want to give more.
Profiling and screening means that you receive information that is appropriate, relevant and timely and which we hope will enhance your experience as a supporter. It means that we can raise more funds, sooner and most cost-effectively than we would have otherwise, essential in our fight against prostate cancer.
Depending on your settings or the privacy policies for social media and messaging services like Facebook, WhatsApp or Instagram, you might give us permission to access information from those accounts or services.
Infographics, videos, podcasts, posters, articles and other informational content displayed on the website are expected to be shared via social media platforms to maximise the reach of our campaign. However, the Fund will not be held responsible for any unauthorised reproduction of our content that may be used to further any party’s agenda.
The Fund is an apolitical entity that is committed to engage with all stakeholders who share our values to further our mission and cause for prostate cancer.
The Fund is strongly against the circulation of fake news and misinformation. It is our position that all information circulated on social media platforms purportedly to be sourced from our campaign and this website should always be fact checked against the Fund’s original content and intent.
We aspire to provide support to individuals and their families affected by prostate cancer, and may collect personal data in order to best do that.
The Prostate Cancer Society Malaysia (“PCSM”) is a third party who runs their own support groups for newly-diagnosed patients, patients undergoing treatment, survivors, and affected family members. While the Fund will take all the necessary steps to ensure that all information conveyed on the website is medically accurate and up-to-date, the Fund and this website will not be liable for any liabilities or damages arising from any of your engagement with, and participation in activities organised by, any prostate cancer support group under PCSM.
We always take the position that any personal health decision by any individual shall only be made in consultation with qualified medical professionals registered with the Malaysian Medical Council.
While the website provides an avenue to users who would like to support the Fund’s mission financially, users are not obliged to donate. All funds will be channeled to the Fund and shall never be channeled to any particular individual’s bank account.
Content and information on the website may be translated into different languages from English to ensure greater access for the public. Users acknowledge that while best efforts will be used to ensure that all content and information is accurate and up-to-date, the English version shall always prevail in the event of any ambiguity and contradiction between the languages.
While prostate cancer is a disease that impacts only men, the Fund is a supporter of equal opportunity and does not condone any gender discrimination. Family members regardless of gender and spouses are typically also impacted by a prostate cancer diagnosis.
We reserve the right to amend the terms and conditions at any time, so please check it from time to time. We will notify you or any significant changes in the way we treat personal information in a prominent position on our website. By continuing to use our website, you will be deemed to have accepted such changes.
Last Change Date: 31 October 2020